Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Heart Failure | Unmet Need | Chronic Heart Failure | US/FR/DE/UK | 2021

Login to access report north_east
Contact sales account_box

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases, but proven pharmacological treatment options are limited. In February 2021, the FDA approved Entresto, an angiotensin receptor-neprilysin inhibitor (ARNI) marketed by Novartis for HFpEF, making it the first approved therapy for this subpopulation. Despite a long list of clinical trial failures, the HFpEF pipeline has some promising candidates, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs). Substantial market opportunity remains for effective therapies to treat this heterogeneous and highly prevalent population.

QUESTIONS ANSWERED

  • Which drug attributes are the most influential in driving cardiologists’ prescribing decisions?
  • Which therapies used in the treatment of HFpEF do cardiologists perceive as performing the best on efficacy, safety and tolerability, and convenience of administration attributes?
  • What are the major areas of opportunity for drug developers in HFpEF treatment, and what is their likelihood of being fulfilled in the near future?
  • What are the trade-offs that surveyed cardiologists are willing to make across key attributes when considering new treatments for HFpEF?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in March 2021.

Key companies: Novartis, Pfizer

Key drugs: ACE inhibitors, ARBs, ARNIs (Entresto, sacubitril / valsartan), beta blockers, calcium channel blockers, diuretics, MRAs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east